Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or m6A protein synthesis routes

Abstract Plitidepsin is an antitumoral compound safe for treating COVID-19 that targets the translation elongation factor eEF1A. Here we detect that plitidepsin decreases de novo cap-dependent translation of SARS-CoV-2 and non-viral RNAs but affects less than 13% of the host proteome, thus preservin...

Full description

Saved in:
Bibliographic Details
Main Authors: Elisa Molina Molina, Joan Josep Bech-Serra, Eloi Franco-Trepat, Ignasi Jarne, Daniel Perez-Zsolt, Roger Badia, Eva Riveira-Muñoz, Edurne Garcia-Vidal, Lluís Revilla, Sandra Franco, Ferran Tarrés-Freixas, Núria Roca, Gerardo Ceada, Karl Kochanowski, Dàlia Raïch-Regué, Itziar Erkizia, Rytis Boreika, Antoni E. Bordoy, Laia Soler, Sonia Guil, Jorge Carrillo, Julià Blanco, Miguel Ángel Martínez, Roger Paredes, Alejandro Losada, Pablo Aviles, Carmen Cuevas, Júlia Vergara-Alert, Joaquim Segalés, Bonaventura Clotet, Ester Ballana, Carolina de la Torre, Nuria Izquierdo-Useros
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-56151-y
Tags: Add Tag
No Tags, Be the first to tag this record!